Seminars in Nephrology
Volume 30, Issue 1 , Pages 81-89 , January 2010

Disparities in Kidney Transplant Outcomes: A Review

  • Elisa J. Gordon, PhD, MPH

      Affiliations

    • Institute for Healthcare Studies and Department of Surgery, Division of Organ Transplantation, Feinberg School of Medicine, Northwestern University, Chicago, IL
    • Corresponding Author InformationAddress reprint requests to Elisa J. Gordon, PhD, MPH, Research Associate Professor, Institute for Healthcare Studies, Department of Surgery, Division of Organ Transplantation, Feinberg School of Medicine, Northwestern University, 750 N Lakeshore Dr, 10th Floor, Chicago, IL 60611
    • ,
  • Daniela P. Ladner, MD, MPH

      Affiliations

    • Department of Surgery, Division of Organ Transplantation, Northwestern University, Chicago, IL
    • ,
  • Juan Carlos Caicedo, MD

      Affiliations

    • Department of Surgery, Division of Organ Transplantation, Northwestern University, Chicago, IL
    • Hispanic Transplant Program, Northwestern University, Chicago, IL
    • ,
  • John Franklin, MD, MSc

      Affiliations

    • Departments of Psychiatry and Surgery, Northwestern University, Chicago, IL

References 

  1. Magee CC, Pascual M. Update in renal transplantation. Arch Intern Med. 2004;164:1373–1388
  2. Laupacis A, Keown P, Pus N, Krueger H, Ferguson B, Wong C, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int. 1996;50:235–242
  3. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341:1725–1730
  4. Loubeau PR, Loubeau JM, Jantzen R. The economics of kidney transplantation versus hemodialysis. Prog Transplant. 2001;11:291–297
  5. Eckhoff DE, Young CJ, Gaston RS, Fineman SW, Deierhoi MH, Foushee MT, et al. Racial disparities in renal allograft survival: a public health issue?. J Am Coll Surg. 2007;204:894–903
  6. Braveman P. Health disparities and health equity: concepts and measurement. Annu Rev Public Health. 2006;27:167–194
  7. National Institutes of Health. The health of the nation: highlights of the Healthy People 2000 goals: 1995 Report on Progress. http://www.odphp.osophs.dhhs.gov/pubs/hp2000/pdf/midcourse/midcourse/midrvwl.pdf[accessed 2007 December]
  8. Nelson A. Unequal treatment: confronting racial and ethnic disparities in health care. J Natl Med Assoc. 2002;94:666–668
  9. Siminoff LA, Burant CJ, Ibrahim SA. Racial disparities in preferences and perceptions regarding organ donation. J Gen Intern Med. 2006;21:995–1000
  10. Gordon EJ. The ethics of Medicare policy: increasing transplant access and survival. DePaul Law Review. 2006;54:101–122
  11. Gordon EJ. What “race” cannot tell us about access to kidney transplantation. Camb Q Healthc Ethics. 2002;11:134–141
  12. Butkus DE, Meydrech EF, Raju SS. Racial differences in the survival of cadaveric renal allografts (Overriding effects of HLA matching and socioeconomic factors). N Engl J Med. 1992;327:840–845
  13. Isaacs RB, Nock SL, Spencer CE, Connors AF, Wang XQ, Sawyer R, et al. Racial disparities in renal transplant outcomes. Am J Kidney Dis. 1999;34:706–712
  14. Meier-Kriesche HU, Ojo A, Magee JC, Cibrik DM, Hanson JA, Leichtman AB, et al. African-American renal transplant recipients experience decreased risk of death due to infection: possible implications for immunosuppressive strategies. Transplantation. 2000;70:375–379
  15. Opelz G, Pfarr E, Engelmann A, Keppel E. Kidney graft survival rates in black cyclosporine-treated recipients (Collaborative Transplant Study). Transplant Proc. 1989;21:3918–3920
  16. Gjertson DW. Determinants of long-term survival of adult kidney transplants: a 1999 UNOS update. Clin Transpl. 1999;341–352
  17. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000;342:605–612
  18. Hardinger KL, Stratta RJ, Egidi MF, Alloway RR, Shokouh-Amiri MH, Gaber LW, et al. Renal allograft outcomes in African American versus Caucasian transplant recipients in the tacrolimus era. Surgery. 2001;130:738–747
  19. Katznelson S, Gjertson DW, Cecka JM. The effect of race and ethnicity on kidney allograft outcome. Clin Transpl. 1995;379–394
  20. Saunders PH, Banowsky LH, Reichert DF. Survival of cadaveric renal allografts in Hispanic as compared with Caucasian recipients. Transplantation. 1984;37:359–362
  21. Chertow GM, Milford EL. Poorer graft survival in African-American transplant recipients cannot be explained by HLA mismatching. Adv Ren Replace Ther. 1997;4:40–45
  22. Press R, Carrasquillo O, Nickolas T, Radhakrishnan J, Shea S, Barr RG. Race/ethnicity, poverty status, and renal transplant outcomes. Transplantation. 2005;80:917–924
  23. Milgrom M, Gharagozloo H, Gomez C, Contreras N, Lopez E, Esquenazi V, et al. Results of renal transplantation in Miami analyzed by race. Transplant Proc. 1989;21:3934–3936
  24. Kasiske BL, Cohen D, Lucey MR, Neylan JF. Payment for immunosuppression after organ transplantation (American Society of Transplantation). JAMA. 2000;283:2445–2450
  25. Gjertson DW. A multi-factor analysis of kidney graft outcomes at one and five years posttransplantation: 1996 UNOS Update. Clin Transpl. 1996;343–360
  26. Caicedo JC, Butt Z, Halgrimson W, Preczewski L, Daud A. Outcomes after kidney transplantation in Hispanics. Am J Transplant. 2008;8:626
  27. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int. 2000;57:307–313
  28. US Renal Data System. USRDS 2007 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, National Institutes of Health. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2007;
  29. Naiman N, Baird BC, Isaacs RB, Koford JK, Habib AN, Wang BJ, et al. Role of pre-transplant marital status in renal transplant outcome. Clin Transplant. 2007;21:38–46
  30. Schaeffner ES, Mehta J, Winkelmayer WC. Educational level as a determinant of access to and outcomes after kidney transplantation in the United States. Am J Kidney Dis. 2008;51:811–818
  31. Chakkera HA, O'Hare AM, Johansen KL, Hynes D, Stroupe K, Colin PM, et al. Influence of race on kidney transplant outcomes within and outside the Department of Veterans Affairs. J Am Soc Nephrol. 2005;16:269–277
  32. Kalil RS, Heim-Duthoy KL, Kasiske BL. Patients with a low income have reduced renal allograft survival. Am J Kidney Dis. 1992;20:63–69
  33. Goldfarb-Rumyantzev AS, Koford JK, Baird BC, Chelamcharla M, Habib AN, Wang BJ, et al. Role of socioeconomic status in kidney transplant outcome. Clin J Am Soc Nephrol. 2006;1:313–322
  34. Petersen E, Baird BC, Barenbaum LL, Leviatov A, Koford JK, Shihab F, et al. The impact of employment status on recipient and renal allograft survival. Clin Transplant. 2008;22:428–438
  35. Gill JS, Abichandani R, Kausz AT, Pereira BJ. Mortality after kidney transplant failure: the impact of non-immunologic factors. Kidney Int. 2002;62:1875–1883
  36. Cho YW, Terasaki PI, Cecka JM. New variables reported to the UNOS registry and their impact on cadaveric renal transplant outcomes—a preliminary study. In:  Cecka JM,  Terasaki PI editor. Clinical Transplants. Los Angeles, CA: UCLA Tissue Typing Laboratory; 1995;
  37. Woodward RS, Schnitzler MA, Lowell JA, Spitznagel EL, Brennan DC. Effect of extended coverage of immunosuppressive medications by Medicare on the survival of cadaveric renal transplants. Am J Transplant. 2001;1:69–73
  38. Krieger NR, Becker BN, Heisey DM, Voss BJ, D'Alessandro AM, Becker YT, et al. Chronic allograft nephropathy uniformly affects recipients of cadaveric, nonidentical living-related, and living-unrelated grafts. Transplantation. 2003;75:1677–1682
  39. Butkus DE, Dottes AL, Meydrech EF, Barber WH. Effect of poverty and other socioeconomic variables on renal allograft survival. Transplantation. 2001;72:261–266
  40. Koyama H, Cecka JM, Terasaki PI. Kidney transplants in black recipients (HLA matching and other factors affecting long-term graft survival). Transplantation. 1994;57:1064–1068
  41. Yeates K, Wiebe N, Gill J, Sima C, Schaubel D, Holland D, et al. Similar outcomes among black and white renal allograft recipients. J Am Soc Nephrol. 2009;20:172–179
  42. Kasiske BL, Snyder JJ, Skeans MA, Tuomari AV, Maclean JR, Israni AK. The geography of kidney transplantation in the United States. Am J Transplant. 2008;8:647–657
  43. Axelrod DA, Guidinger MK, Finlayson S, Schaubel DE, Goodman DC, Chobanian M, et al. Rates of solid-organ wait-listing, transplantation, and survival among residents of rural and urban areas. JAMA. 2008;299:202–207
  44. Gordon EJ, Prohaska T, Siminoff LA, Minich PJ, Sehgal AR. Can focusing on self-care reduce disparities in kidney transplantation outcomes?. Am J Kidney Dis. 2005;45:935–940
  45. Smith SR, Butterly DW. Declining influence of race on the outcome of living-donor renal transplantation. Am J Transplant. 2002;2:282–286
  46. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 2002;62:311–318
  47. Kerman RH, Kimball PM, Van Buren CT, Lewis RM, Kahan BD. Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation. 1991;51:338–342
  48. Milford EL, Ratner L, Yunis E. Will transplant immunogenetics lead to better graft survival in blacks? (Racial variability in the accuracy of tissue typing for organ donation: the fourth American workshop). Transplant Proc. 1987;19:30–32
  49. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients (U.S. Renal Transplant Mycophenolate Mofetil Study Group). Transplantation. 1997;64:1277–1282
  50. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine (FK506 Kidney Transplant Study Group). Transplantation. 1998;65:515–523
  51. Gaston RS, Hudson SL, Deierhoi MH, Barber WH, Laskow DA, Julian BA, et al. Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression. Transplantation. 1992;53:103–109
  52. Lindholm A, Welsh M, Alton C, Kahan BD. Demographic factors influencing cyclosporine pharmacokinetic parameters in patients with uremia: racial differences in bioavailability. Clin Pharmacol Ther. 1992;52:359–371
  53. First MR, Schroeder TJ, Monaco AP, Simpson MA, Curtis JJ, Armenti VT. Cyclosporine bioavailability: dosing implications and impact on clinical outcomes in select transplantation subpopulations. Clin Transplant. 1996;10:55–59
  54. Koyama H, Cecka JM. Race effects. Clin Transpl. 1991;269–280
  55. Baez Y, Giron F, Nino-Murcia A, Rodriguez J, Salcedo S. Experience with Alemtuzumab (Campath-1H) as induction agent in renal transplantation followed by steroid-free immunosuppression. Transplant Proc. 2008;40:697–699
  56. Katznelson S, Cecka JM. Immunosuppressive regimens and their effects on renal allograft outcome. Clin Transpl. 1996;361:71
  57. Gordon EJ, Caicedo JC. Ethnic advantages in kidney transplant outcomes: the Hispanic Paradox at work?. Nephrol Dial Transplant. 2009;24:1103–1109
  58. Cosio FG, Dillon JJ, Falkenhain ME, Tesi RJ, Henry ML, Elkhammas EA, et al. Racial differences in renal allograft survival: the role of systemic hypertension. Kidney Int. 1995;47:1136–1141
  59. Oriol R, Le Pendu J, Chun C. Influence of the original disease, race, and center on the outcome of kidney transplantation. Transplantation. 1982;33:22–26
  60. Epstein AM, Ayanian JZ, Keogh JH, Noonan SJ, Armistead N, Cleary PD, et al. Racial disparities in access to renal transplantation—clinically appropriate or due to underuse or overuse?. N Engl J Med. 2000;343:1535–1544
  61. Kasiske BL, Snyder JJ, Matas AJ, Ellison MD, Gill JS, Kausz AT. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol. 2002;13:1358–1364
  62. Kayler LK, Rasmussen CS, Dykstra DM, Ojo AO, Port FK, Wolfe RA, et al. Gender imbalance and outcomes in living donor renal transplantation in the United States. Am J Transplant. 2003;3:452–458
  63. Swanson SJ, Hypolite IO, Agodoa LY, Batty DS, Hshieh PB, Cruess D, et al. Effect of donor factors on early graft survival in adult cadaveric renal transplantation. Am J Transplant. 2002;2:68–75
  64. Tankersley MR, Gaston RS, Curtis JJ, Julian BA, Deierhoi MH, Rhynes VK, et al. The living donor process in kidney transplantation: influence of race and comorbidity. Transplant Proc. 1997;29:3722–3723
  65. Chavalitdhamrong D, Gill J, Takemoto S, Madhira BR, Cho YW, Shah T, et al. Patient and graft outcomes from deceased kidney donors age 70 years and older: an analysis of the Organ Procurement Transplant Network/United Network of Organ Sharing database. Transplantation. 2008;85:1573–1579
  66. Siegal B, Greenstein S. Compliance and noncompliance in kidney transplant patients: cues for transplant coordinators. J Transpl Coord. 1999;9:104–108
  67. Kiley DJ, Lam CS, Pollak R. A study of treatment compliance following kidney transplantation. Transplantation. 1993;55:51–56
  68. Rovelli M, Palmeri D, Vossler E, Bartus S, Hull D, Schweizer R. Noncompliance in renal transplant recipients: evaluation by socioeconomic groups. Transplant Proc. 1989;21:3979–3981
  69. De Geest S, Borgermans L, Gemoets H, Abraham I, Vlaminck H, Evers G, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation. 1995;59:340–347
  70. Didlake RH, Dreyfus K, Kerman RH, Van Buren CT, Kahan BD. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc. 1988;20:63–69
  71. Schweizer RT, Rovelli M, Palmeri D, Vossler E, Hull D, Bartus S. Noncompliance in organ transplant recipients. Transplantation. 1990;49:374–377
  72. Isaacs RB, Conners A, Nock S, Spencer C, Lobo P. Noncompliance in living-related donor renal transplantation: the United Network of Organ Sharing experience. Transplant Proc. 1999;31:19S-20
  73. Chisholm MA, Vollenweider LJ, Mulloy LL, Jagadeesan M, Wynn JJ, Rogers HE, et al. Renal transplant patient compliance with free immunosuppressive medications. Transplantation. 2000;70:1240–1244
  74. Woodward RS, Page TF, Soares R, Schnitzler MA, Lentine KL, Brennan DC. Income-related disparities in kidney transplant graft failures are eliminated by Medicare's immunosuppression coverage. Am J Transplant. 2008;8:2636–2646
  75. Yen EF, Hardinger K, Brennan DC, Woodward RS, Desai NM, Crippin JS, et al. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant. Am J Transplant. 2004;4:1703–1708
  76. Dor A, Pauly MV, Eichleay MA, Held PJ. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ. 2007;7:73–111
  77. Horl WH, de Alvaro F, Williams PF. Healthcare systems and end-stage renal disease (ESRD) therapies—an international review: access to ESRD treatments. Nephrol Dial Transplant. 1999;14(Suppl 6):10–15
  78. Jha V. End-stage renal care in developing countries: the India experience. Ren Fail. 2004;26:201–208
  79. Naicker S. End-stage renal disease in sub-Saharan and South Africa. Kidney Int Suppl. 2003;83:S119–S122
  80. Sakhuja V, Sud K. End-stage renal disease in India and Pakistan: burden of disease and management issues. Kidney Int Suppl. 2003;83:S115–S118
  81. Barsoum RS. Overview: end-stage renal disease in the developing world. Artif Organs. 2002;26:737–746
  82. Emovon OE, Op't Holt C, Browne BJ. Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome?. Clin Transplant. 2002;16(Suppl 7):45–48
  83. Caicedo JC, Butt Z, Halgrimson W, Preczewski L, Daud A. Outcomes after kidney transplantation in Hispanics (Hispanic edition). Am J Transplant. 2008;8(Suppl 2):626
  84. Groth CG, Chapman JR. The global alliance for transplantation. Transplant Proc. 2006;38:356–357
  85. Agency for Healthcare Research and Quality. Literacy and health outcomes (Summary. Evidence report/technology assessment, number 87. #04-E007-1 January). In: Rockville, MD: Department of Health and Human Services; 2004;p. 259
  86. Sue S, Dhindsa MK. Ethnic and racial health disparities research: issues and problems. Health Educ Behav. 2006;33:459–469
  87. Stewart AL, Napoles-Springer AM. Advancing health disparities research: can we afford to ignore measurement issues?. Med Care. 2003;41:1207–1220
  88. Peralta CA, Shlipak MG, Fan D, Ordonez J, Lash JP, Chertow GM, et al. Risks for end-stage renal disease, cardiovascular events, and death in Hispanic versus non-Hispanic white adults with chronic kidney disease. J Am Soc Nephrol. 2006;17:2892–2899
  89. Saha S. Improving literacy as a means to reducing health disparities. J Gen Intern Med. 2006;21:893–895
  90. Gordon EJ, Wolf MS. Health literacy among kidney transplant recipients. Prog Transplant. 2009;19:25–34
  91. Rodriguez RA, Sen S, Mehta K, Moody-Ayers S, Bacchetti P, O'Hare AM. Geography matters: relationships among urban residential segregation, dialysis facilities, and patient outcomes. Ann Intern Med. 2007;146:493–501
  92. Klassen AC, Hall AG, Saksvig B, Curbow B, Klassen DK. Relationship between patients' perceptions of disadvantage and discrimination and listing for kidney transplantation. Am J Public Health. 2002;92:811–817
  93. Higgins RS, Fishman JA. Disparities in solid organ transplantation for ethnic minorities: facts and solutions. Am J Transplant. 2006;6:2556–2562
  94. Russell CL. Culturally responsive interventions to enhance immunosuppressive medication adherence in older African American kidney transplant recipients. Prog Transplant. 2006;16:187–195quiz 96
  95. Carter JM, Winsett RP, Rager D, Hathaway DK. A center-based approach to a transplant employment program. Prog Transplant. 2000;10:204–208
  96. Chang CF, Winsett RP, Gaber AO, Hathaway DK. Cost-effectiveness of post-transplantation quality of life intervention among kidney recipients. Clin Transplant. 2004;18:407–414
  97. Chisholm MA, Mulloy LL, Jagadeesan M, DiPiro JT. Impact of clinical pharmacy services on renal transplant patients' compliance with immunosuppressive medications. Clin Transplant. 2001;15:330–336
  98. Bodenheimer TE, Wagner H, Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002;288:1775–1779
  99. Englesbe MJ, Pelletier SJ, Kheterpal S, O'Reilly M, Campbell DA. A call for a national transplant surgical quality improvement program. Am J Transplant. 2006;6:666–670
  100. Lockridge RS. The direction of end-stage renal disease reimbursement in the United States. Semin Dial. 2004;17:125–130

 Supported by a Career Development Award from the National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD (DK063953 to E.J.G.).

PII: S0270-9295(09)00175-2

doi: 10.1016/j.semnephrol.2009.10.009

Seminars in Nephrology
Volume 30, Issue 1 , Pages 81-89 , January 2010

Article Tools